MDGL | Madrigal PharmaceuticalsNASDAQHealthcareCommon stock golden cross and death cross projections, cross tests and history

$396.32
-$34.83 (-8.08%)

Madrigal Pharmaceuticals (MDGL) is a NASDAQ-listed common stock that Cruxta has tracked for 50/200 crosses since 2017.

The 50 SMA has sat below the 200 on the daily since Oct 2026, with no cross projected inside the 30 bars Cruxta tracks. On both the daily and the 4-hour, price sits below the 50 and the 200; on the weekly it is between the two.

Timeframe summary

Daily as of 3 Nov 16:00 ET

Price
below both $396.32 vs 50 $494.64 / 200 $499.10
Projection
No cross projected
Test
Cross test window open, no test bar yet
Last cross
Death cross 30 Oct 2026 ยท projected 27 bars out

Weekly as of 30 Oct 16:00 ET

Price
between the two $430.36 vs 50 $509.36 / 200 $333.44
Projection
No cross projected
Test
No active test
Last cross
Golden cross week of 23 Jan 2023 ยท projected 6 bars out

4-hour as of 3 Nov 13:30 ET

Price
below both $401.70 vs 50 $461.86 / 200 $509.06
Projection
No cross projected
Test
No active test
Last cross
Death cross 8 Oct 2026 ยท projected 25 bars out

Cross history

33
crosses on record since 2017
16 golden17 death
Full cross history โ†’
CrossedDirectionTimeframeProjectedCross test
30 Oct 2026Death moderatedaily27 bars outActive Cross Test
8 Oct 2026Death4-hour25 bars outNot tested
3 Sep 2026Golden4-hour1 bar out1 bar cross test
2 Sep 2026Death4-hour1 bar outNot tested
24 Apr 2026Golden4-hour26 bars out5 bar cross test

About MDGL

ExchangeNASDAQ
InstrumentCommon stock
Median $ volume, 60 d$124M
4-hour coverageYes, since Oct 2025
History on recordSince 2017
SectorHealthcare
Cap bandlarge

Cruxta · 50/200 moving-average crosses on US equities. Recorded crosses are observations. Projected crosses are projections, not advice.